Sorry, you need to enable JavaScript to visit this website.

Testing the safety of avelumab and axitinib on patients with kidney cancer (JAVELIN Renal 100)

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination With Axitinib (AG-013736) in Patients With Previously Untreated Advanced Renal Cell Cancer

Category & Conditions: Cancer
Medicine: Bavencio (avelumab) INLYTA®(AXITINIB) Identifier (NCT): NCT02493751
Protocol ID: B9991002
Open Plain Language Summary Result: Click here